Pleural empyema medical therapy

Jump to navigation Jump to search

Empyema Main Page

Pleural empyema Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pleural empyema from other Diseases

Epidemiology and Demographics

Screening

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

ECG

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pleural empyema medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pleural empyema medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pleural empyema medical therapy

CDC on Pleural empyema medical therapy

Pleural empyema medical therapy in the news

Blogs on Pleural empyema medical therapy

Directions to Hospitals Treating Pleural empyema

Risk calculators and risk factors for Pleural empyema medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

The mainstay of therapy for empyema includes:[1] controlling the infectious focus, drainage of fluid and pus, re-expansion of the lung. This involes the use of antimicrobial agents, thrombolytics,[2][3] and drainage of the pleural space.[4][5][6] Pharmacologic therapies for acute empyema include either Ceftriaxone, Nafcillin or Oxacillin, Vancomycin or Linezolid, or TMP-SMX. The preferred regimen for subacute and chronic empyema is a combination of Clindamycin and Ceftriaxone.

Medical Therapy

Definitive treatment for empyema entails drainage of the infected pleural fluid. A chest tube may be inserted, often using ultrasound guidance. Intravenous antibiotics are given. If this is insufficient, surgical debridement of the pleural space may be required.

Antibiotic Therapy

Following are the guidelines to treat Pleural empyema .[7][8]


▸ Click on the following categories to expand treatment regimens.

Pleural Empyema

  ▸   Neonates

  ▸   Infants/Children

  ▸   Adult

Neonates
Preferred Regimen
Age 0-7 days and Weight ≤ 2000 gm
If MSSA
Nafcillin 25 mg/kg IV q12h
OR
Oxacillin 25 mg/kg IV q12h
If MRSA
Vancomycin 12.5 mg/kg IV q12h
Age 7-28 days and Weight ≤ 2000 gm
If MSSA
Nafcillin 25 mg/kg q8h
OR
Oxacillin 25 mg/kg IV q12h
If MRSA
Vancomycin 15 mg/kg IV q12h
Age 0-7 days and Weight > 2000 gm
If MSSA
Nafcillin 25 mg/kg q8h
OR
Oxacillin 25 mg/kg IV q12h
If MRSA
Vancomycin 18 mg/kg IV q12h
Age 7-28 days and Weight > 2000 gm
If MSSA
Nafcillin37 mg/kg q6h
OR
'Oxacillin 37 mg/kg q6h
If MRSA
Vancomycin 22 mg/kg q12h
Infants/Children
Preferred Regimen
Cefotaxime 100 mg/kg IV q8h
OR
Ceftriaxone 100 mg/kg IV q24h
'If MSSA
Vancomycin 40 mg/kg/day IV in 3-4 divided doses
With or Without
▸ 'Cefotaxime 100 mg/kg IV q8h
OR
Ceftriaxone 100 mg/kg IV q24h
If H.Influenzae suspected
Adult
Preferred Regimen
For Strep. pneumoniae or Streptococcus sp (Group A)
Cefotaxime 2 gm IV q8h
OR
Ceftriaxone 2 gm IV q24h or Penicillin 12-18 million units IV divided q4h/day
OR
Ampicillin 8-12 gm IV divided q4h/day
For Staph. aureus
MSSA
Nafcillin2 gm IV q4h
OR
Oxacillin 2 gm IV q4h
MRSA
Vancomycin 10-15 mg/kg IV q8-12h
OR
Linezolid 600 mg IV q12h
For H. influenzae
Ceftriaxone 2 gm IV q24h
Subacute/Chronic
Clindamycin 450-900 mg IV q8h
PLUS
Ceftriaxone 2 gm IV q24h
Alternative Regimens
For Strep. pneumoniae or Streptococcus sp (Group A)
Vancomycin 1 gm IV q12h
For H. influenzae
TMP-SMX (5-10 mg/kg/day as trimethoprim component) IV/po in 2-3 divided doses
OR
Ampicillin Sulbactam 3 gm IV q6h (child dose 100-300 mg/kg/day IV divided q6h)
Chronic
Cefoxitin 2 gm IV q6-8h
OR
Imipenem 0.5 gm IV q6h
OR
Piperacillin Tazobactam 3.375 gm IV q6h (or 4-hour infusion of 3.375 gm q8h)
OR
Ampicillin Sulbactam 3 gm IV q6h

Surgical management

  • Antibiotic treatment should be continued for atleast 4 to 6 weeks. Sometimes it may be needed for a longer time. A CT and chest tube output should be used to confirm a complete fluid drainage with no residual locules present.
  • Other modes of draining pleural fluid are tube thoracostomy, video-assisted thoracoscopic surgery (VATS), open decortication, and open thoracostomy.

Tube thoracostomy

  • Least invasive
  • Preferred for unilocuated effusions and free-flowing fluid.
  • For solitary lesions a CT scan or ultrasound is used to guide the tube.
  • For lesions more than one multiple small catheters are used to drain.
  • When draining empyema fluid, thoracostomy tubes are typically placed using either an ultrasound or CT-guided approach. When multiple loculations are present, we typically place small-bore catheters, as multiple tubes may be needed to drain the multiloculated pleural space.
  • A trial showed no difference between different sizes of thoracostomy tube. Smaller tubes were preferred due to decreased pain.[9][10]
  • British thoracic society recommends flushing the tube every 6 hrs to remain patent.[11]. Smaller tubes are more prone to failure due to blockage.[12]. Chest tubes are placed atleast till the cavity closes or drainage falls below 50 ml/day.
  • Confirm correct placement of the tube using CT scans and checking drainage .

Fibrinolytic agents

  • Surgical thoracotomy with decortication is preferred to thorascopic debridement in patients who have more pleural thickness , larger cavity and adhesions.[19][20][21]

Post surgical complications

An empyema forming in a space created by surgery with or without a fistula between bronchus and pleura should be treated carefully.[22]Available treatment options are :

  1. Irrigation with antibiotic
  2. Filling up the space with pedicles of muscles
  3. Closing the fistula surgically

Open Thoracostomy

An incision is made through the chest wall to aid drainage at the inferior border of the cavity . A chest tube is inserted and left to drain the remaining cavity . This process is time consuming and requires at least 2-3 months. However a few side effects of anesthesia and chest tube infection still remain.

References

  1. Reichert M, Hecker M, Witte B, Bodner J, Padberg W, Weigand MA; et al. (2016). "Stage-directed therapy of pleural empyema". Langenbecks Arch Surg. doi:10.1007/s00423-016-1498-9. PMID 27815709.
  2. Porcel JM, Valencia H, Bielsa S (2016). "Manual Intrapleural Saline Flushing Plus Urokinase: A Potentially Useful Therapy for Complicated Parapneumonic Effusions and Empyemas". Lung. doi:10.1007/s00408-016-9964-2. PMID 27866276.
  3. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C; et al. (2011). "Intrapleural use of tissue plasminogen activator and DNase in pleural infection". N Engl J Med. 365 (6): 518–26. doi:10.1056/NEJMoa1012740. PMID 21830966. Review in: Ann Intern Med. 2011 Dec 20;155(12):JC6-9
  4. Ashbaugh DG (1991). "Empyema thoracis. Factors influencing morbidity and mortality". Chest. 99 (5): 1162–5. PMID 2019172.
  5. Light RW (1995). "A new classification of parapneumonic effusions and empyema". Chest. 108 (2): 299–301. PMID 7634854.
  6. Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B; et al. (2000). "Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline". Chest. 118 (4): 1158–71. PMID 11035692.
  7. Bradley, JS.; Byington, CL.; Shah, SS.; Alverson, B.; Carter, ER.; Harrison, C.; Kaplan, SL.; Mace, SE.; McCracken, GH. (2011). "The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America". Clin Infect Dis. 53 (7): e25–76. doi:10.1093/cid/cir531. PMID 21880587. Unknown parameter |month= ignored (help)
  8. Rahman, NM.; Maskell, NA.; West, A.; Teoh, R.; Arnold, A.; Mackinlay, C.; Peckham, D.; Davies, CW.; Ali, N. (2011). "Intrapleural use of tissue plasminogen activator and DNase in pleural infection". N Engl J Med. 365 (6): 518–26. doi:10.1056/NEJMoa1012740. PMID 21830966. Unknown parameter |month= ignored (help)
  9. Maskell, NA.; Davies, CW.; Nunn, AJ.; Hedley, EL.; Gleeson, FV.; Miller, R.; Gabe, R.; Rees, GL.; Peto, TE. (2005). "U.K. Controlled trial of intrapleural streptokinase for pleural infection". N Engl J Med. 352 (9): 865–74. doi:10.1056/NEJMoa042473. PMID 15745977. Unknown parameter |month= ignored (help)
  10. Rahman, NM.; Maskell, NA.; Davies, CW.; Hedley, EL.; Nunn, AJ.; Gleeson, FV.; Davies, RJ. (2010). "The relationship between chest tube size and clinical outcome in pleural infection". Chest. 137 (3): 536–43. doi:10.1378/chest.09-1044. PMID 19820073. Unknown parameter |month= ignored (help)
  11. Davies, CW.; Gleeson, FV.; Davies, RJ. (2003). "BTS guidelines for the management of pleural infection". Thorax. 58 Suppl 2: ii18–28. PMID 12728147. Unknown parameter |month= ignored (help)
  12. Horsley, A.; Jones, L.; White, J.; Henry, M. (2006). "Efficacy and complications of small-bore, wire-guided chest drains". Chest. 130 (6): 1857–63. doi:10.1378/chest.130.6.1857. PMID 17167009. Unknown parameter |month= ignored (help)
  13. Jerjes-Sánchez, C.; Ramirez-Rivera, A.; Elizalde, JJ.; Delgado, R.; Cicero, R.; Ibarra-Perez, C.; Arroliga, AC.; Padua, A.; Portales, A. (1996). "Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial". Chest. 109 (6): 1514–9. PMID 8769503. Unknown parameter |month= ignored (help)
  14. Temes, RT.; Follis, F.; Kessler, RM.; Pett, SB.; Wernly, JA. (1996). "Intrapleural fibrinolytics in management of empyema thoracis". Chest. 110 (1): 102–6. PMID 8681611. Unknown parameter |month= ignored (help)
  15. Davies, RJ.; Traill, ZC.; Gleeson, FV. (1997). "Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection". Thorax. 52 (5): 416–21. PMID 9176531. Unknown parameter |month= ignored (help)
  16. Bouros, D.; Schiza, S.; Tzanakis, N.; Chalkiadakis, G.; Drositis, J.; Siafakas, N. (1999). "Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study". Am J Respir Crit Care Med. 159 (1): 37–42. doi:10.1164/ajrccm.159.1.9803094. PMID 9872815. Unknown parameter |month= ignored (help)
  17. Diacon, AH.; Theron, J.; Schuurmans, MM.; Van de Wal, BW.; Bolliger, CT. (2004). "Intrapleural streptokinase for empyema and complicated parapneumonic effusions". Am J Respir Crit Care Med. 170 (1): 49–53. doi:10.1164/rccm.200312-1740OC. PMID 15044206. Unknown parameter |month= ignored (help)
  18. Thomson, AH.; Hull, J.; Kumar, MR.; Wallis, C.; Balfour Lynn, IM. (2002). "Randomised trial of intrapleural urokinase in the treatment of childhood empyema". Thorax. 57 (4): 343–7. PMID 11923554. Unknown parameter |month= ignored (help)
  19. Thommi, G.; Nair, CK.; Aronow, WS.; Shehan, C.; Meyers, P.; McLeay, M. "Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema". Am J Ther. 14 (4): 341–5. doi:10.1097/01.mjt.0000208275.88120.d1. PMID 17667208.
  20. Tuncozgur, B.; Ustunsoy, H.; Sivrikoz, MC.; Dikensoy, O.; Topal, M.; Sanli, M.; Elbeyli, L. (2001). "Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial". Int J Clin Pract. 55 (10): 658–60. PMID 11777287. Unknown parameter |month= ignored (help)
  21. Tokuda, Y.; Matsushima, D.; Stein, GH.; Miyagi, S. (2006). "Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis". Chest. 129 (3): 783–90. doi:10.1378/chest.129.3.783. PMID 16537882. Unknown parameter |month= ignored (help)
  22. CLAGETT, OT.; GERACI, JE. (1963). "A procedure for the management of postpneumonectomy empyema". J Thorac Cardiovasc Surg. 45: 141–5. PMID 14021469. Unknown parameter |month= ignored (help)

Template:WH Template:WS